Dianne Pulte

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research, National Marine Sanctuary Foundation, Food and Drug Administration

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia”.

US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia

Journal of Clinical Oncology(2025)10.1200/jco-25-01369

N/A

0.104DataRank · unranked

1 citations

Dianne Pulte, Lori A. Ehrlich, Alexei Ionan, Spencer R. Haupert, Jonathon Vallejo +15 more

FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4271

N/A

0DataRank · unranked

82 citations

Kelly J. Norsworthy, Yaping Wang, Qing Xu, Hisham Qosa, Ramadevi Gudi +8 more

FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1005

N/A

0DataRank · unranked

5 citations

Dianne Pulte, Xin Wang, Jonathon Vallejo, Ritu Chadda, Nan Zheng +10 more